NCT01941056已完成1 期
Phase I Evaluation of a CMV-MVA Triplex Vaccine: Safety and Biologically Effective Dose in Healthy Volunteers With or Without Prior Immunity to CMV and Vaccinia
City of Hope Medical Center2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2014年1月5日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Successful completion of 2 injections without dose-limiting toxicity (DLT) according to the Division of Microbiology and Infectious Diseases (DMID) adult toxicity tables
研究概览
简要总结
This phase I trial studies the side effects and the best dose of vaccine therapy in healthy volunteers with or without previous exposure to cytomegalovirus. Vaccines made from a gene-modified virus may help the body build an immune response and may help prevent cytomegalovirus infection.
详细描述
PRIMARY OBJECTIVES:
I. To establish a biological optimal dose of the cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine (multi-CMV epitope modified vaccinia Ankara vaccine).
II. To determine if the vaccine is safe and well tolerated in healthy volunteers at these doses.
SECONDARY OBJECTIVES:
I. To provide preliminary evidence of CMV-MVA Triplex vaccine driven expansion of CMV-specific immune responses that would support further evaluation of this vaccine in hematopoietic cell transplantation (HCT) recipients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sodium range from within normal institutional limits to less than a grade I toxicity
- •Potassium range from within normal institutional limits to less than a grade I toxicity
- •Chloride range from within normal institutional limits to less than a grade I toxicity
- •Carbon dioxide range from within normal institutional limits to less than a grade I toxicity
- •Glucose range from within normal institutional limits to less than a grade I toxicity
- •Alkaline phosphatase (AP) range from within normal institutional limits to less than a grade I toxicity
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT) range from within normal institutional limits to less than a grade I toxicity
- •Blood urea nitrogen (BUN) range from within normal institutional limits to less than a grade I toxicity
- •Creatinine range from within normal institutional limits to less than a grade I toxicity
- •Lactic dehydrogenase (LDH) range from within normal institutional limits to less than a grade I toxicity
- •Total bilirubin range from within normal institutional limits to less than a grade I toxicity
- •Uric acid range from within normal institutional limits to less than a grade I toxicity
- •Albumin > lower limit of normal institutional limits
- •White blood count range from within normal institutional limits to less than a grade I toxicity
- •Hemoglobin (HGB) range from within normal institutional limits to less than a grade I toxicity
- •Hematocrit (HCT) range from within normal institutional limits to less than a grade I toxicity
- •Platelet count is within the lower limit of normal institutional limits and not more than 1.5 times the upper limit of normal institutional limits
- •Hepatitis B virus (HBV) surface antigen negative and hepatitis C virus (HCV) seronegative; human immunodeficiency virus (HIV)-1 seronegative
- •Currently not taking daily medications for chronic or intercurrent illness; those medications which are excepted from this rule are thyroid replacement, estrogen replacement, dietary vitamins and protein supplements, and any medications not known or likely to be immunosuppressive, as determined by the principal investigator (PI)
- •No surgery in past 6 months which required general anesthesia, but minor procedures, such as dental surgery and superficial diagnostic biopsies, are permitted
- •No diagnosis which has been associated with immunodeficiency
- •No active infection for which the subject is receiving treatment
- •Framingham Risk Score for cardiovascular disease =< 10%; no history of heart disease, e.g. previous treated arrhythmia or myocardial infarction; no horizontal positioning-induced or activities of normal living exercise-induced shortness of breath; no history of stroke or claudication; no current treatment with medication for high cholesterol or other lipid abnormality; a documented electrocardiogram (ECG) and cardiac troponin must be within normal institutional limits in the past 30 days; "normal ECG with sinus tachycardia" or " normal ECG with sinus bradycardia" is allowable based on a history of absent cardiac/exercise related symptoms as determined by the P.I. in consultation with a senior staff cardiologist
- •No history of or prior treatment for diabetes type 1 or diabetes type 2
- •Women of childbearing age must have a negative urine pregnancy test and must not be planning to become pregnant within the next 6 months
- •No history of adverse events with a prior smallpox vaccination
- •SECONDARY ELIGIBILITY CRITERIA:
- •It is anticipated that there could be a delay of 1-3 months between screening and actual vaccination; alternatively, there could be a delay due to availability of the vaccine; therefore, prior to registration for vaccination, the following secondary eligibility criteria must be met:
- •If not tested in past 4 months, serum chemistries and blood counts are within normal limits; hepatitis B virus (HBV) surface antigen negative and hepatitis C virus (HCV) seronegative; HIV-1 antibody negative
- •Women of childbearing age must have a urine pregnancy test performed within 48 hours of each vaccine administration with a negative result
- •Laboratory values prior to booster injection may include grade 1 laboratory abnormalities, but any grade >= grade 2 will exclude the subject from a booster injection
排除标准
- •Any previous condition, or one that becomes known during the screening period, that would suggest that the individual could be immunologically impaired, or for which this study would pose a danger to him/herself or about which the P.I., in evaluating the subject for eligibility, determines that this exclusion is appropriate
- •Subjects are excluded who have a history of cancer other than basal cell skin cancer, or any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc. as determined by the PI. In addition, allergic diatheses as define by a history of asthma, anaphylaxis, or generalized urticaria, or by daily use of antihistamines, episodic (more than once in past 3 months) inhalational medications including steroidal agents, non-steroidal agents, or cromolyn sodium
- •Subjects with severe migraine headaches (more than one per month on average in the past 6 months or requiring preventive medications) are excluded
- •Any of the following cardiac findings of ECG abnormality:
- •Conduction disturbance (complete left or right bundle branch block, intraventricular conduction disturbance with QRS > 120 ms, atrioventricular block [AV] block of any degree, and corrected QT [QTc] prolongation > 450 msec for men and > 460 msec for women)
- •Repolarization (ST segment or T wave) abnormality
- •Significant atrial or ventricular arrhythmia, including frequent ectopy (e.g., 2 premature ventricular contractions in a row; and
- •Evidence of past myocardial infarction
- •Any previous condition, or one that becomes known during the screening period, that would suggest that the technicians and health professionals involved in the study would be exposed to specific infectious risk
- •Treatment with whole or subunit CMV or poxvirus vaccine in the last 12 months
- •Men with partners of child-bearing potential and women of child-bearing potential who are not willing to use medically effective birth control methods, e.g. contraceptive pill, condom, or diaphragm, and continue this for 6 weeks after the second and last dose of vaccine
- •Subjects who have had a live vaccine =< 30 days prior to administration of study vaccine or subjects who are =< 2 weeks within administration of inactivated vaccines (e.g. influenza vaccine)
- •Persons who are employed by or are a student at City of Hope and are in a chain of command that reports directly to persons listed on the protocol as Principal Investigator or Co-Investigator.
研究组 & 干预措施
Treatment (CMV-MVA Triplex vaccine)
Experimental
Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
干预措施: multi-CMV epitope modified vaccinia Ankara vaccine (Biological)
Treatment (CMV-MVA Triplex vaccine)
Experimental
Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Successful completion of 2 injections without dose-limiting toxicity (DLT) according to the Division of Microbiology and Infectious Diseases (DMID) adult toxicity tables
时间窗: Up to 28 days
次要结局
- Evidence of CMV-MVA Triplex vaccine driven expansion of CMV-specific immune responses to support further evaluation of this vaccine in HCT recipients.(Up to 1 year)
- Frequency of polyfunctional cluster of differentiation (CD)4+ and CD8+ T cells recognizing CMV Ag, expressed as concentrations(Up to 1 year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult SubjectsEquine EncephalitisNCT04131595Bavarian Nordic45
已完成
1 期
Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung CancerNon Small Cell Lung CancerNCT00633724Fukushima Medical University9
进行中（未招募）
2 期
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid Cell NeoplasmLymphoblastic LymphomaMyeloproliferative NeoplasmNon-Hodgkin LymphomaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeHodgkin LymphomaMyelofibrosisNCT04060277City of Hope Medical Center7
已完成
1 期
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected SubjectsHIV InfectionsNCT00623259Bavarian Nordic15
招募中
1 期
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell TransplantCytomegaloviral InfectionHematopoietic Cell Transplant RecipientNCT03354728City of Hope Medical Center80